Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Carles Escriu"'
Autor:
Igor Gomez-Randulfe, Sofía Silva Díaz, Carles Escriu, Saara Mohammed, Riyaz Shah, Javier David Benitez Fuentes, Samantha Cox, Federico Monaca, Emilio Bria, María Rosario García-Campelo, Benjamin Crook, Toby Talbot, Rita Leporati, Kirsty Balachandran, Tom Newsom-Davis, Sarah Hughes, Laura Cove-Smith, Paul Taylor, Fiona Blackhall, Raffaele Califano
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Background and objectives: Second-line treatment for small-cell lung cancer (SCLC) is primarily guided by the time elapsed since the last platinum dose. Rechallenge with carboplatin and etoposide has demonstrated superior outcomes compared to topotec
Externí odkaz:
https://doaj.org/article/b761da8d4bca4511a117872a9490eebc
Autor:
Shobana Anpalakhan, Prerana Huddar, Roya Behrouzi, Alessio Signori, Judith Cave, Charles Comins, Alessio Cortellini, Alfredo Addeo, Carles Escriu, Hayley McKenzie, Gloria Barone, Lisa Murray, David J. Pinato, Christian Ottensmeier, Sara Campos, Sethupathi Muthuramalingam, Samuel Chan, Fabio Gomes, Giuseppe L. Banna
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundThe Spinnaker study evaluated survival outcomes and prognostic factors in patients with advanced non-small-cell lung cancer receiving first-line chemoimmunotherapy in the real world. This sub-analysis assessed the immunotherapy-related adve
Externí odkaz:
https://doaj.org/article/4fdf002d926347d087b59097c087c44f
Autor:
Jason Lester, Carles Escriu, Sarah Khan, Emma Hudson, Talal Mansy, Andrew Conn, Samuel Chan, Ceri Powell, Juliet Brock, John Conibear, Lauren Nelless, Vaneet Nayar, Xiaohui Zhuo, Adeline Durand, Amerah Amin, Peter Martin, Xinke Zhang, Vivek Pawar
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
Abstract Background The treatment landscape for advanced non-small cell lung cancer (aNSCLC) has evolved rapidly since immuno-oncology (IO) therapies were introduced. This study used recent data to assess real-world treatment patterns and clinical ou
Externí odkaz:
https://doaj.org/article/dc0b45bae2d243a6977fe1c09edaddf0
Autor:
Shobana Anpalakhan, Prerana Huddar, Roya Behrouzi, Alessio Signori, Judith Cave, Charles Comins, Alessio Cortellini, Alfredo Addeo, Carles Escriu, Hayley McKenzie, Gloria Barone, Lisa Murray, Gagan Bhatnagar, David J. Pinato, Christian Ottensmeier, Fabio Gomes, Giuseppe Luigi Banna
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 2, p 1746 (2023)
GCSF prophylaxis is recommended in patients on chemotherapy with a >20% risk of febrile neutropenia and is to be considered if there is an intermediate risk of 10–20%. GCSF has been suggested as a possible adjunct to immunotherapy due to increased
Externí odkaz:
https://doaj.org/article/a4ef063e10254e818fa9542482fba528
Publikováno v:
BMC Pulmonary Medicine, Vol 19, Iss 1, Pp 1-8 (2019)
Abstract Background Dose intensity and dose density of first line Platinum and Etoposide (PE) do not influence Overall Survival (OS) of Small Cell Lung Cancer (SCLC) patients. The effect of treatment length, however, remains unclear. Current guidelin
Externí odkaz:
https://doaj.org/article/cc59d7c5517a43b986714cf98bb6b74f
Autor:
Carles Escriu, Sridhar Rathinam, Doreen Kahangire, Saurabh Nagar, Keith Davis, Maria Jimenez, Martin Sandelin, Jason Chow
Publikováno v:
Lung Cancer. 178:S17
Autor:
Shobana Anpalakhan, Prerana Huddar, Roya Behrouzi, Alessio Signori, Judith Cave, Charles Comins, Alessio Cortellini, Alfredo Addeo, Carles Escriu, Hayley McKenzie, Gloria Barone, Lisa Murray, David Pinato, Christian Ottensmeier, Fabio Gomes, Sethupathi Muthuramalingam, Samuel Chan, Sara Campos, Giuseppe Banna
Publikováno v:
Lung Cancer. 178:S33
Autor:
Carles Escriu
Publikováno v:
Video-Assisted Thoracic Surgery. 7:11-11
Autor:
Katherine Piddock, Hritik Nautiyal, Mohammed Ahmed, Melanie Barron, Neeraj Bhalla, Tim Cook, Sarah Cubbin, Gershan Davis, Rebecca Dobson, Carles Escriu, Hala Ghoz, Clare Hart, Mark Johnston, Christopher McManus, Alexander Montasem, Hayley Sohl, Sarah Rose, Victoria Tippett, Helen Wong, David Cobben
Publikováno v:
Lung Cancer. 165:S41
Autor:
Helen Kalirai, Maria Marples, Sarah E. Coupland, Paul Nathan, Carles Escriu, Bertil Damato, Ernest Marshall, Matthew Bickerstaff, Catrin Tudur Smith
Publikováno v:
Journal of Clinical Oncology. 30:8523-8523
8523 Background: The median overall survival (OS) for metastatic uveal melanoma is less than 6 months with a median progression free survival(PFS) of 3 months. No systemic or regional therapy has shown a survival advantage over best supportive care.